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A R T I C L E   I N F O 
 (
A B S T R A C T 
The use of complementary and alternative medicine (CAM) has attracted much 
attention in recent years and has become a significant topic of debate within the 
healthcare sector. Many patients suffering from serious conditions such as cancer, 
Alzheimer’s disease, diabetes and lower back pain seek alternative therapies 
including CAM biological products. Clinicians and healthcare practitioners need to 
be aware of the available clinical evidence relating to CAM-based therapies when 
advising patients and recommending options. This review presents the recent 
clinical data investigating the efficacy of CAM therapies for disease management 
among these groups of patients. A number of cancer drugs are listed which have 
been developed from natural sources and which have recently gained approval from 
the EMA and FDA based on clinical trials. Reasons for using CAM and the most 
frequently used CAM therapies are mentioned as well as the degree of improvement 
of quality of life based on patients’ experiences.  
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INTRODUCTION 
According to National Institutes of Health, 
complementary and alternative medicine (CAM) is 
defined as a group of heterogeneous group of medical 
and healthcare systems, substances, supplements and 
procedures that do not count to be a part of 
mainstream of conventional medicine  (Baruah, Borua 
et al. 2016). These include medication-based therapies 
in which herbal or mineral products are used and non-
medication practices such as acupuncture, 
aromatherapy, Ayurvedic medicine, massage, 
chiropractic and osteopathy  (Hyodo, Amano et al. 
2005). 
According to the World Health Organisation (WHO), 
around 80% of the world’s population depends on 
indigenous therapy that is closely correlated with  
CAM (Lim, Sadarangani et al. 2005). The use of CAM 
is widespread in many countries, such as Australia 
and the UK. CAM has been used by almost 40% of 
adults in the US, 50% in Canada, and 75% in France 
(Bradshaw 2016; Jatau, Aung et al. 2016).  In the UK, 
the prevalence rate of CAM use among the general 
population is about 46%, that is, where one or more 
CAM therapies are used during a lifetime (Bishop and 
Lewith 2010). The availability of CAM treatments via 
the National Health Service (NHS) provisions has 
increased significantly in the UK and the NHS 
currently provides funds for the following therapies: 
herbal medicine, acupuncture, homeopathy, 
osteopathy and chiropractic (Thomas and Coleman 
2004). However, many other CAM-based therapies 
are offered outside NHS provision (Thomas, Coleman 
et al. 2001). 
Why have CAM-based therapies increased in 
popularity among patients with serious diseases? 
There are several reasons for trying this kind of 
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medicine, including perceived effectiveness, 
accessibility, affordability, improvements in physical 
and emotional wellbeing, prevention of ill health, 
desperation or dissatisfaction with some aspects of 
conventional medicine such as the cost and the 
adverse effect, a positive inclination towards it as well 
as its relaxing effects (Ernst and White 2000; 
Molassiotis, Fernadez-Ortega et al. 2005). It has been 
estimated that 96% of doctors have not been given 
basic knowledge of CAM therapies (Frass, Strassl et 
al. 2012). This may have resulted in communication 
gaps between clinicians and patients about the 
potential usefulness of CAM, leading to ineffective 
disease management.  
In this review we highlight the usage of CAM 
therapies in cancer, Alzheimer’s, diabetes and low 
back pain patients. We report the most frequently 
used CAM modalities and evaluate how these can 
facilitate the management of these dangerous 
diseases. Evidence from recently published clinical 
studies is cited in evaluating the effectiveness of CAM 
therapies among these groups of patients.  
CAM and Cancer 
Despite the advances made by conventional medicine 
for cancer treatment, interest in CAM continues to 
grow at an exponential rate and its popularity in 
cancer care has been well documented (Chatwin and 
Tovey 2004). A survey conducted by researchers 
revealed that cancer patients began using CAM 
alongside conventional treatment because the latter 
sometimes fails to cure the majority of common 
cancers (Scott, Kearney et al. 2005). Patients also found 
that the CAM-based treatments are accessible, 
affordable and relatively safe when compared to 
conventional medicine (Oh, Butow et al. 2010; Erku 
2016) 
Interestingly, despite the demographic origin of the 
cancer patients, studies reveal that CAM users are 
generally well educated, with an overall higher 
standard of education than non-CAM users (Scott, 
Kearney et al. 2005; Farooqui, Hassali et al. 2015; 
Sullivan, Gilbar et al. 2015). It may be that those with 
higher educational qualifications are more inclined to 
investigate the potential benefits of new or alternative 
therapies, especially for serious diseases such as 
cancer.  
Considering the type of CAM used, cancer patients 
may use one or more CAM modality in the 
management of their disease and there is clear 
regional variability in the choice of CAM modalities. 
In the UK, relaxation and meditation techniques, 
spiritual or faith healing, reflexology, aromatherapy, 
and mineral and herbal products are the most 
common modalities used by cancer patients (Scott, 
Kearney et al. 2005). In Malaysia, Japan, Palestine and 
Australia, nutritional supplements, herbal products 
and multivitamins are the most common CAM 
therapies (Hyodo, Amano et al. 2005; Farooqui, 
Hassali et al. 2015; Sullivan, Gilbar et al. 2015; Ali-
Shtayeh, Jamous et al. 2016). Multivitamins are also 
regularly used in the US, as well as chiropractic or 
osteopathic manipulation, movement therapies, 
special diets; such as organic vegetables and fruit, 
gluten free, casein free, no processed sugars or no 
salicylates; acupuncture, naturopathy, or different 
combinations of these therapies (Shih, Chiang et al. 
2009; Perrin, Coury et al. 2012; Falci, Shi et al. 2016). It 
is clear that these regional variations in the CAM 
preferences of cancer patients may be attributable to 
differences in cultures and traditions in terms of 
practices and food, e.g. in Asia some of the consumed 
food is low in fat, high in fibers and full of fresh fruits 
and vegetables, thus the most commonly used CAM 
is associated with nutritional supplements and 
multivitamins. From the literature, breast, lung and 
colorectal cancers are the most frequent diagnoses 
among CAM users (Scott, Kearney et al. 2005).  It has 
been highlighted by several studies that patients 
using CAM in combination with conventional 
medicine were those in the more advanced stages of 
cancer. This is an indication that patients in the later 
stages are keen to try all possible therapies offered by 
healthcare professionals as they are often desperate to 
survive and have been fighting their disease for a long 
period of time (Sullivan, Gilbar et al. 2015).  
It is apparent, then, that CAM-based therapies can 
help to improve the quality of life of cancer patients, 
and recent years have also witnessed the discovery for 
new anti-cancer compounds from natural sources. 
Such new compounds show structural diversity with 
great biological functionality. Furthermore, this 
chemical variety plays an important role in shaping 
the pharmacological diversity of compounds and 
interacting with multiple targets as cancer is known as 
a complex disease. In addition, the continuing 
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discovery of natural lead is paving the way for 
medicinal chemists to synthesise modified substances 
with similar or even stronger effects (Cragg and 
Pezzuto 2016). Therefore, scientist focus on searching 
of new anti-tumour agents from natural sources as 
many plant and marine derived compounds are 
successfully used in the clinic for cancer therapy. 
Taxol, vinblastine and camptothecin, for example, are 
well known examples of approved and successful 
plant-based drugs for cancer patients. Other natural 
sources, such as marine organisms (e.g. ecteinascidin 
743 and halichondrin B) and microbes (e.g. bleomycin 
and doxorubicin), have also provided anti-tumour 
lead compounds (Cragg and Pezzuto 2016).  
To approve that natural products are a continuous 
source of biologically active compounds, several anti-
cancer compounds have recently been approved by 
the European Medical Association (EMA) and the 
Food and Drug Administration (FDA) (Basmadjian, 
Zhao et al. 2014; Newman and Cragg 2016). The 
compounds listed below (Table. 1)  have either been 
isolated directly from their natural origin, modified 
from natural pharmacophores or obtained from 
natural sources, such as biological macromolecules, 
peptides or proteins isolated from living 
organisms/cell line.  
Istodax 
Istodax is a novel natural compound that was 
approved by the FDA for the treatment of patients 
with cutaneous T-cell lymphoma in 2009. This unique 
compound, romidepsin, was isolated from the Gram-
negative Chromobacterium violaceum, which was 
isolated from a Japanese soil sample (VanderMolen, 
McCulloch et al. 2011). High response rates have been 
observed in a Phase II study of both cutaneous and 
peripheral T-cell lymphoma and a Phase III study is 
still ongoing in combination with several anti-tumour 
agents (Bates, Eisch et al. 2015). 
Kadcyla 
This lead is a combination of trastuzumab coupled to 
emtansine, the latter is a maytansine derivative being 
a biosynthetic product of the Putterlickia spp.root-
associated endophytic bacterial community (LoRusso, 
Weiss et al. 2011; Kusari, Kusari et al. 2016). The FDA 
has approved this natural compound in 2013 for 
HER2-positive metastatic breast cancers based on a 
Phase III study (Peddi and Hurvitz 2014). 
Halaven 
This is a synthetic derivative inspired by a natural 
marine product, halichondrin B, which has been 
recently approved by the FDA. It has been named 
eribulin mesylate and works as a non-taxane 
microtubule dynamics inhibitor (Yu, Zheng et al. 
2013). This marine-derived compound can be used to 
treat metastatic breast cancer, as a Phase III study has 
shown an elevation in survival rates of the tested 
population (Cortes, O'Shaughnessy et al. 2011). 
Kyprolis 
Epoxomicin, isolated from Actinomycetes, has been 
modified to obtain a new anti-tumour lead named 
carfilzomib (Meng, Mohan et al. 1999). This new 
derivative has shown to yield effective results with 
manageable toxicity in multiple myeloma patients, 
leading to its approval by the FDA in 2012 (Muchtar, 
Gatt et al. 2016).  
PICN (Paclitaxel derivative) 
PICN is a new formulation of paclitaxel which 
contains polymer and lipid mixtures; that has been 
approved by the FDA in 2012 (Newman and Cragg 
2016). This novel formulation offers efficacy and 
potential safety in breast cancer patients, as evaluated 
in a Phase III trial (Jain, Gupte et al. 2016). 
Biological macromolecule 
Biological macromolecule refers to a large peptide 
that either isolated from an organism or developed by 
biotechnological means in a surrogate host (Newman 
and Cragg 2016). Blincyto is a biological 
macromolecule working as an immunotherapeutic 
antibody called blinatumomab. Its approval in 2014 is 
based on clinical trials involving B-cell acute 
lymphoblastic leukemia patients (Sheridan 2015). 
Nivolumab and pembrolizumab are human IgG4 
programmed death 1 antibodies which have been 
approved by the FDA in 2015 (Shu and Rizvi 2016). 
Phase III studies of nivolumab involving patients who 
had metastatic melanoma without BRAF mutation 
demonstrated significant improvements in melanoma 
patients (Robert , Long  et al. 2015). The safety and 
efficacy of pembrolizumab was also shown in a study 
of metastatic melanoma and non–small-cell lung 
patients (Garon, Rizvi et al. 2015; Raedler 2015a). 
Ramucirumab, in the form of an IgG1 monoclonal 
antibody VEGFR-2 antagonist called Cyramza, is an 
angiogenesis inhibitor (Fuchs, Tomasek et al. 2013; 
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Wang, Wang et al. 2015). It has been approved 
recently for the treatment of patients with advanced 
gastric or gastroesophageal junction adenocarcinoma 
(Fuchs, Tomasek et al. 2013). 
CAM and Alzheimer’s disease 
Alzheimer’s disease is a neurodegenerative disorder 
and a major cause of dementia in the elderly. It is 
characterised by many features such as the 
deterioration of structure and/or function of neurons 
associated with functional disorders of language, 
memory, cognition, emotion, character and behaviour 
(Ip, Tsim et al. 2014; Liu, Kong et al. 2014). It has been 
reported that traditional herbal medicine products are 
the most popular CAM modality for this condition in 
comparison to other CAM-based therapies (Posadzki, 
Ernst et al. 2012). 
The pathogenesis of Alzheimer’s disease reveals that 
oxidative stress, depletion or inadequate synthesis of 
neurotransmitters and the rapid degradation of 
neurotransmitters in the synaptic clef due to rapid 
enzyme action results in changes in the biological 
mechanisms of neurons, leading to symptoms of the 
disease (Rasool, Malik et al. 2014). Therefore, agents 
with anti-oxidative, anticholinesterase and 
stimulating acetylcholine release properties are 
useful. Many traditionally used medicinal plants have 
demonstrated complementary cognitive benefits in 
the treatment of Alzheimer’s disease. Moreover, there 
is strong clinical evidence to support the use of herbal 
medicine in both the treatment and prevention of 
Alzheimer’s disease (Liu, Kong et al. 2014). 
The efficacy of traditional herbal medicine has been 
confirmed by laboratory studies leading to the 
isolation of bioactive phytochemicals. For example, 
isolated anti-oxidative compounds such as piperine, 
from Piper nigrum, and sinapine, from Brassica species, 
have been shown to be effective agents in 
neurodegenerative disorders (Rasool, Malik et al. 
2014). Neuroprotective agents such as ginkgetin, 
ginkoglides-A and B, from Ginkgo biloba, and 
anticholinesterase candidates like harmine (from 
Peganum harmala), galantamine (from Galanthus spp.) 
as well as vasicine and vasicol (from Adhatoda vasica) 
have also demonstrated therapeutic effects in the 
treatment of Alzheimer’s (Heinrich and Lee Teoh 
2004; Yoo and Park 2012; Ali, Hamed et al. 2013; 
Rasool, Malik et al. 2014). Moreover, these findings 
are further supported by clinical studies conducted 
recently in which G. biloba shows potential benefit in 
patients with Alzheimer’s disease, including the 
improvement of cognitive function and activities of 
daily living (Yang, Wang et al. 2016). Also, natural 
compounds antagonizing glutamate receptors are 
reported such as huperzine A, derived from Huperzia 
serrata  (Qian and Ke 2014). 
CAM and diabetes 
Diabetes mellitus is a metabolic syndrome and one of 
the pandemic diseases, with a prevalence of 400 
million around the world (Yang, Chang et al. 2015). In 
diabetes management, studies reveal that 
acupuncture, massage, exercise, and herbal products 
can offer satisfaction to diabetic patients and have 
been shown to be effective alongside prescribed 
conventional medication. The adoption rate of CAM 
therapies by diabetic patients is high, since many of 
these modalities are low-cost, easily available in the 
community and meet lifestyle requirements 
(Pumthong, Nathason et al. 2015). 
Interestingly, the uptake of CAM therapies depends 
on their popularity within a given population; for 
example, CAM is commonly used in countries where 
herbal medicine is common practice in primary health 
care such as Palestine and India (Ali-Shtayeh, Jamous 
et al. 2012; Baruah, Borua et al. 2016). Conversely, 
CAM-based therapies have been shown to be used 
less frequently by diabetic patients in Australia 
(Sibbritt, Davidson et al. 2015). 
Natural digestive enzyme inhibitor from plants have 
been widely used for the treatment of Type-II diabetes 
and approved by FDA like acarbose, isolated from a 
number of species of Actinomycetes (Al Sibae and 
McGuire 2009; Bedekar, Shah et al. 2010). 
Furthermore, human clinical studies have 
demonstrated the effectiveness of anti-diabetic herbs 
such as Bidens pilosa. The hypoglycemic effects of this 
plant alone or in combination with conventional anti-
diabetic drugs include reduction of fasting blood 
glucose and increase of fasting insulin levels. 
Importantly, as safety is a major issue with herbal 
products, the clinical data demonstrate clearly that B. 
pilosa formulation is safe in healthy subjects (Yang, 
Chang et al. 2015).  
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Table 1. List of anti-cancer compounds from natural sources which have been recently approved based on clinical trials. 




Istodax Romidepsin  Cutaneous and peripheral T-cell lymphoma I,II,III Yes 
Kadcyla Trastuzumab 
emtansine 
HER2-positive metastatic breast cancer I,II,III Yes 
Halaven Eribulin mesylate Metastatic breast cancer I,II,III Yes 
Kyprolis Carfilzomib  Multiple myeloma I,II,III  
PICN Paclitaxel 
nanoparticle 
Breast cancer I,II,III FDA 
Blincyto Blinatumomab  B-cell acute lymphoblastic leukaemia I,II,III Yes 
Optivo Nivolumab Metastatic melanoma without BRAF 
mutation 
I,II,III Yes 
Keytruda Pembrolizumab Metastatic melanoma and non–small-cell 
lung cancer 
I,II,III Yes 




CAM and back pain 
The problem of lower back pain is of great cost to 
health services as sufferers comprise the second 
largest group seeking primary care consultation in 
industrial countries (Quinn, Hughes et al. 2006). 
Osteopathy, chiropractic and massage are the most 
frequently accessed therapies for low back pain, and 
there is evidence to support their effectiveness 
(Murthy, Sibbritt et al. 2015). Acupuncture, herbal 
medicine, yoga and homeopathy are also reported to 
be popular CAM choices for this condition (Murthy, 
Adams et al. 2015).  
Randomised controlled trials have been conducted on 
low back pain sufferers who were exposed to 
chiropractic manipulative therapy in conjunction with 
standard therapy, consisting of medication and 
general home care advice. Researchers concluded that 
the addition of chiropractic manipulation improved 
physical functioning in the tested population and 
demonstrated a significant advantage in the reduction 
of back pain compared to those receiving the standard 
therapy alone (Goertz, Long et al. 2013). The effect of 
yoga practice is also studied in low back pain patients 
and is found to offer good short-term effectiveness 
and moderate long-term effectiveness in controlled 
trials (Cramer, Lauche et al. 2013).   
CONCLUSIONS 
The use of CAM is very well documented by a 
substantial proportion of patients suffering from 
serious diseases such as cancer, neurodegenerative 
disorders, diabetes and lower back pain. This review 
has provided valuable insights into the prevalence of 
CAM use, the most commonly used CAM modalities, 
and clinical studies approving its efficacy among 
these groups of patients. There is evidence that 
natural sources can provide novel and structurally 
diverse chemical compounds possessing anti-cancer 
properties and many have been approved recently by 
the EMA and FDA, for example, Kadcylaand 
Istodax. Although there is beneficial effects of using 
CAM as shown here based on clinical studies, there is 
lack of useful and effective communication between 
clinicians and patients about CAM therapies, since 
many CAM users engage in this kind of treatment 
without consulting their orthodox healthcare 
providers  (Hyodo, Amano et al. 2005; Evans, Shaw et 
al. 2007). This is one of the factors which has led to the 
debate among healthcare practitioners about the place 
of CAM within the framework of mainstream 
medicine (Kissane, Bultz et al. 2011).  
It is clear that patients with serious conditions as 
mentioned here have tried any of CAM modalities 
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based on personal preference but how can this CAM 
practice be engaged efficiently in the framework of 
health care and been prescribed by healthcare 
professionals.  For this debate and to address this 
issue, a research strategy is needed to evaluate the 
efficacy of commonly used therapies, patient’s 
attitudes regarding CAM, the effects of CAM 
outcomes and the safety of CAM. Also, this is required 
to identify the most relevant CAM therapies for 
specific clinical settings, to personalise this treatment 
and to understand user experiences (Fischer, Lewith 
et al. 2014). The outcome of this research will pave the 
way to make a stronger contribution to the need of 
patients and healthcare professionals enabling the 
engagement of CAM in healthcare framework. 
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